ProMIS Neurosciences Inc. (T:PMN*CA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEDAR
Company Contact
Address: SUITE 200, 1920 YONGE STREET
TORONTO ON M4S 3E2
Tel: 1-617-9010785
Website: https://promisneurosciences.com
IR: See website
<
Key People
Eugene Williams
Executive Chairman of the Board
Neil Cashman
Co-Founder, Chief Scientific Officer, Director
Daniel E. Geffken
Chief Financial Officer
Gavin Malenfant
Chief Operating Officer
Larry Altstiel
Chief Medical Officer
Johanne Kaplan
Chief Development Officer
David Wishart
Chief Physics Officer
   
Business Overview
ProMIS Neurosciences, Inc. is a Canada-based development-stage biotechnology company. The Company is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company is focused on the discovery engine, which is based on the use of two complementary algorithms: ProMIS and Collective Coordinates, which are used to predict targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. The Company is focused on developing antibody therapeutics for AD, ALS and PD. The Company has a wholly owned subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).
Financial Overview
For the three months ended 31 March 2022, Promis Neurosciences Inc revenues increased from C$0K to C$14K. Net loss decreased 59% to C$3.1M. Revenues reflect Interest earned increase from C$0K to C$8K, Sales and royalty income increase from C$0K to C$5K. Lower net loss reflects FV/Uls Adjust on Derivatives for Hedging increase from C$7M (expense) to C$2.2M (income), Share in net loss of joint venture decrease from C$3K (expense) to C$0K.
Employees: 5 as of Dec 31, 2021
Reporting Currency: Canadian Dollars
Enterprise value: $39.15M as of Mar 31, 2022
Annual revenue (TTM): $0.03M as of Mar 31, 2022
EBITDA (TTM): -$14.98M as of Mar 31, 2022
Net annual income (TTM): -$7.26M as of Mar 31, 2022
Free cash flow (TTM): -$15.13M as of Mar 31, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 7,195,529 as of Jul 25, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.